The post-holder will lead a programme of research within the Pneumococcal Conjugate Vaccine Impact Study (PCVIS).
This is a longitudinal study, funded by Gavi, The Vaccine Alliance, to determine the long-term impact of the PCV programme in Kenya and guide vaccine policy in consultation with the Kenya National Immunisation Technical Advisory Group (KENITAG) and the National Vaccines and Immunization Program within the Ministry of Health.
The post holder will be expected to contribute to the further development of the research programme (including development of their own proposals), scientific leadership, and collaborate with local, national and international partners.
The ideal post holder will have experience in epidemiology and infectious diseases and working in resource-poor settings.
The post holder will be expected to maintain the PCVIS surveillance programme and to contribute further to the development of the PCVIS research agenda by developing new ideas for optimizing interventions for the control of pneumococcal disease.
The post-holder will work full-time at the Kenya Medical Research Institute-Wellcome Trust Research Programme in Kilifi. He/she will be responsible to the Principal Investigator (PI) of PCVIS, and will work closely with other project specific staff (Project Manager, Microbiologist) to ensure smooth running of key epidemiological components of the project.
The core project is a before-after study of invasive pneumococcal disease embedded within the demographic surveillance system, with specific analyses for indirect vaccine protection and “serotype replacement disease”.
The post-holder will assist the PI running the core study but will also oversee additional surveillance activities (e.g. for radiologically-confirmed pneumonia) depending on prior experience.
The PCVIS research programme is multi-faceted and the post-holder will be expected to take on one or more specific objectives personally, depending on his/her prior experience and technical skills.
In particular, a candidate with appropriate experience will be expected to design and execute a pragmatic trial of a change in the PCV schedule with herd protection as the target outcome.